Sigma-Aldrich Ipragliflozin

Ipragliflozin is a potent andhighly selective sodium-glucosecotransporter-2 (SGLT2) inhibitor,demonstrating excellent oral bioavailability with an IC50 of 1,876 nM for SGLT1and 7.38 nM for hSGLT2. Ipragliflozin features dose-dependent pharmacokinetics,effectively induces glucosuria, and has been shown to decrease blood glucoselevels, reduce blood pressure, lower body weight, and diminish bothhypoglycaemic risk and abdominal symptoms in diabetic patients. Additionally,Ipragliflozin increases insulin levels in the pancreas and prevents the loss ofinsulin-positive cells in islets of db/db mice. ASP-1941 also maintains afavourable safety profile as monotherapy and is compatible with otherhypoglycaemic agents, such as sulphonyl urea, metformin, pioglitazone, and dipeptidyl peptidase-4 (DPP4)inhibitors. Ipragliflozin has been considered as ananti-obesity and anti-diabetic agent.

Ipragliflozinis used to study glucose transport and metabolism and type 2 diabetes.

Clinically proven, potent, and highly selective SGLT2 inhibitor; anti-diabetic and anti-obesity.

Ipragliflozin is a potent and highly selective SGLT2 inhibitor, demonstrating excellent oral bioavailability with an IC50 of 1,876 nM for SGLT1 and 7.38 nM for hSGLT2. Ipragliflozin features dose-dependent pharmacokinetics, effectively induces glucosuria, and has been shown to decrease blood glucose levels, reduce blood pressure, lower body weight, and diminish both hypoglycemic risk and abdominal symptoms in diabetic patients. Additionally, Ipragliflozin increases insulin levels in the pancreas and prevents the loss of insulin-positive cells in islets of db/db mice. ASP-1941 also maintains a favorable safety profile as monotherapy and is compatible with other hypoglycemic agents, such as sulphonylureas, metformin, pioglitazone, and DPP4 inhibitors.